More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
|Videos|April 25, 2018
ctDNA Increase May Predict Regorafenib Response in Advanced CRC
Author(s)Pashalina Kehagias
In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.
Advertisement
In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.
Advertisement
Related to this article
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Rutika Mehta, MD, MPH, discussed biomarker testing, PD-L1–low treatment, FLOT dosing, early referral, and ctDNA in gastroesophageal cancer.
Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.
Rutika Mehta, MD, MPH, shares her framework for growth factor support, global dose reductions, and dropping agents during FLOT therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5